• Skip to main content
  • Skip to footer

bioSyntagma

Eliminating trial-and-error cancer treatments

  • Technology
  • Company
  • News
  • Contact

Main Content

Data + AI: Our Strategy for Diagnostics and Discovery

We believe that data, not just drugs, will be the cure for cancer

The Problem

Single biomarkers are no longer sufficient to describe complex biological systems such as tumors. Standard diagnostics do not account for factors that contribute to acquired drug resistance, such as heterogeneity.

Making the Map

Mapping the vast affiliation between mutations, expression, and locale collectively creates a Molecular Fingerprint for the biological system.

The Frontier

Combined with artificial intelligence, assessing Molecular Fingerprints for predicting treatment combinations is the next frontier in discovery and diagnostics

“Artificial Intelligence is doing for personalized medicine what Next Generation Sequencing did for genomics. With the rise of algorithmic biomarkers based on spatial molecular analysis, we are finally witnessing the beginning of what personalized medicine promised.”
 
David Richardson – CEO, bioSyntagma

Meet the mPrint Mind™

We have created a neural network that mines Molecular Fingerprints for signatures of disease that predict acquired drug resistance. The mPrint Mind can then recommend guided treatment plans to avoid resistance and relapse in cancer patients.

Footer

Home Technology Company News Contact


2113 S 48th St. Ste 103, Tempe, AZ 85282
info@biosyntagma.com
© 2021 bioSyntagma. All Rights Reserved.